Menu Search
Equities

Cumberland Pharmaceuticals Inc

CPIX:NSQ

Cumberland Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.28
  • Today's Change0.03 / 2.40%
  • Shares traded13.91k
  • 1 Year change-39.34%
  • Beta0.2065
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cumberland Pharmaceuticals Inc's revenues fell -5.85% from 42.01m to 39.55m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 5.57m to a larger loss of 6.28m.
Gross margin82.58%
Net profit margin-27.45%
Operating margin-28.96%
Return on assets-12.35%
Return on equity-32.67%
Return on investment-17.75%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Cumberland Pharmaceuticals Inc fell by 1.44m. However, the company earned 6.09m from its operations for a Cash Flow Margin of 15.41%. In addition the company used 105.70k on investing activities and also paid 7.42m in financing cash flows.
Cash flow per share-0.3954
Price/Cash flow per share--
Book value per share1.87
Tangible book value per share0.3533
More ▼

Balance sheet in USDView more

Cumberland Pharmaceuticals Inc has a Debt to Total Capital ratio of 38.20%, a higher figure than the previous year's 35.38%.
Current ratio1.44
Quick ratio1.26
Total debt/total equity0.6107
Total debt/total capital0.382
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.